Auszug
Man unterscheidet eine ganze Reihe verschiedener Klassen von Chemotherapeutika mit jeweils unterschiedlichem primärem Wirkungsansatz in der Zelle:
-
Antimetabolite, die als kompetitive Hemmer des Nukleinsäurestoffwechsels fungieren (z. B. Cytarabin, 5-Fluorouracil, Gemcitabin);
-
Alkylanzien (z. B. Cyclophosphamid, Ifosfamid, Busulfan);
-
natürlich vorkommende Antibiotika (z. B. Mitomycin, Bleomycin, Anthrazykline);
-
Topoisomerase-I- und -II-Blocker (Topo I: Camptothecin; Topo II: Epipodophyllotoxine);
-
Pflanzenalkaloide:
-
Vincaalkaloide (z. B. Vincristin, Vinblastin, Vinorelbin)
-
Taxane (Paclitaxel, Docetaxel)
-
Epipodophyllinderivate (Etoposid, Teniposid);
-
Platinverbindungen (Cisplatin, Carboplatin, Oxaliplatin).
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
Literatur
Adamson DJA, Thompson WD, Dawson AA, Bennett B, Haites NE (1995) p53 mutation and expression in lymphoma. Br J Cancer 72:150–154
Allan N, Richards S, Shepherd P et al. (1995) UK Medical Research Council randomized multicenter trial of interferonalpha for chronic myeloid leukemia: Improved survival irrespective of cytogenetic response. Lancet 345:1392
Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L (1995) Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particulary in relation to adjuvant systemic therapy and radiotherapy. Nature Medicine 1:1029–1034
Bosari S, Viale G, Bossi G, Maggioni M, Coggi C, Murray JJ, Lee AKC (1994) Cytoplasmic accumulation of p53 protein: an independent prognostic indicator in colorectal adenocarcinomas. Journal of National Cancer Institute 86:681–687
Colombat P, Salles G, Brousse N et al. (2001) Rituximab (anti-CD20 monoclonal antibody) as single firstline therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97:101–106
Czuczman MS, Grillo-Lopez AJ, White CA et al. (1999) Treatment of patients with lowgrade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17:268–276
Evan GI, Vousden KH (2001) Proliferation, cell cycle and apoptosis in cancer. Nature 411:342–348
Feuring-Buske M, Kneba M, Unterhalt M et al. (2000) IDECC2B8 (Rituximab) anti-CD20 antibody treatment in relapsed advancedstage follicular lymphomas: results of a phase-II study of the German Low-Grade Lymphoma Study Group. Ann Hematol 79:493–500
Gjertsen MK, Gaudernack G (1998) Mutated Ras peptides as vaccines in immunotherapy of cancer. Vox Sang 74(Suppl 2): 489–495
Grant S (1998) Ara-C: cellular and molecular pharmacology. Adv Cancer Res 72:197–233
Hamelin R, Laurent-Puig P, Olschwang S et al. (1994) Association of p53 mutations with short survival in colorectal cancer. Gastroenterology 106:42–48
Hawkins DS, Demers GW, Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892–898
Hehlmann R, Heimpel H, Hasford J et al. (1994). Randomized comparison of interferonalpha with busulfan and hydroxyurea in chronic myelogeneous leukemia. Blood 84: 4064–4077
Huhn D, Herrmann R (2001) MedikamentöseTherapie maligner Erkrankungen. Urban & Fischer, München Jena
Lai WC, Bennett M (1998) DNA vaccines. Crit Rev Immunol 18: 449–484
Lee DJ, Corr M, Carson DA (1998) Control of immune responses by gene immunization. Ann Med 30:460–468
Leukemia ICSGoCm (1994) Interferon alpha2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330:820–825
Leukemia ICSGoCM (1998) Longterm follow up of the Italian trial of interferonalpha versus conventional chemotherapy in chronic myeloid leukemia. Blood 92:1541–1548
Ohnishi K, Ohno R, Tomonaga M et al. (1995) A randomized trial comparing interferonalpha with busulfan for newly diagnosed chronic myelogeneous leukemia in chronic phase. Blood 86: 906–916
Piro LD, White CA, Grillo-Lopez AJ (1999) Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory lowgrade or follicular non-Hodgkin’s lymphoma. Ann Oncol 10: 655–661
Rosenberg SA (2001) Progress in human tumour immunology and immunotherapy. Nature 411:380–384
Rouby SE, Thomas A, Rosenberg CR, Potmesil M, Silber R, Newcomb EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82: 3452–3459
Runnebaum IB, Nagarajan M, Bowman M, Soto D, Sukumar S (1991) Mutations in p53 as potential molecular markers for human breast cancer. Proceedings of the National Academy of Sciences USA 88:10657–10661
Schofield J, Robinson W, Murphy J, Rovira D (1994) Low doses of interferonalpha are as effective as higher doses in inducing remissions and prologning survival in chronic myeloid leukemia. Ann Int Med 121:736–744
Schultze JL, Gribben JG, Nadler LM (1998) Tumorspecific adoptive T-cell therapy for CD40+ B-cell malignancies. Curr Opin Oncol 10:542–547
Sun XF, Carstensen JM, Zhang H, Stal O, Wingren S, Hatschek T, Nordenskjold B (1992) Prognostic significance of cytoplasmic p53 oncoprotein in colorectal adenocarcinoma. Lancet 340: 1369–1373
Usami I, Kubota M, Bessho R, Kataoka A, Koishi S, Watanabe K, Sawada M, Lin YW, Akiyama Y, Furusho K (1998) Role of protein tyrosine phosphorylation in etoposideinduced apoptosis and NF-kappa B activation. Biochem Pharmacol 55:185–191
Wu GS, El-Deiry WS (1996) Apoptotic death of tumor cells correlates with chemosensitivity, independent of p53 or bcl-2. Clin Cancer Res 2:623–633
Yamaguchi A, Kurosaka Y, Fushida S, Kanno M, Yonemura Y, Miwa K, Miyazaki I (1992) Expression of p53 protein in colorectal cancer and its relationship to shortterm prognosis. Cancer 70:2778–2784
Yuan ZM, Huang Y, Kraeft SK, Chen LB, Kharbanda S, Kufe D (1996) Interaction of cyclindependent kinase 2 and the Lyn tyrosine kinase in cells treated with 1-beta-D-arabinofuranosylcytosine. Oncogene 13:939–946
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Hiddemann, W., Neubauer, A. (2007). Wirkungsweisen der antineoplastischen Chemo- und Immuntherapie. In: Schölmerich, J. (eds) Medizinische Therapie 2007 | 2008. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-48554-4_20
Download citation
DOI: https://doi.org/10.1007/978-3-540-48554-4_20
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-48553-7
Online ISBN: 978-3-540-48554-4
eBook Packages: Medicine (German Language)